The pharmacological management of Attention Deficit Hyperactivity Disorder (ADHD) and related neurological conditions relies extensively on central nervous system (CNS) stimulants designed to optimize neurotransmitter availability within frontostriatal brain circuits. Across international healthcare jurisdictions spanning the United States, Canada, Brazil, Mexico, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, and Switzerland, clinicians routinely prescribe […]